Clinical Data Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease BioSpaceRhythm Pharmaceuticals' Imcivree reduced fat--while boosting muscle--in patients with Prader-Willi syndrome.Rare DiseaseRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) BioSpace Rhythm Pharmaceuticals’ Imcivree reduced fat–while boosting muscle–in patients with Prader-Willi syndrome. Rare Disease Read full story Post navigation Previous: Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacyNext: Key pipeline drug for Lundbeck delivers in Cushing syndrome Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
